Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

1.16881

Millipore

Fractogel® EMD TMAE (M)

Synonyme(s) :

Biochromatography, Fractogel® Ion exchangers, Ion exchanger for LC (Fractogel® TSK/EMD), Fractogel® EMD TMAE (M)

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
41115711

ligand

(Trimethylammoniumethyl)

Niveau de qualité

400

Description

strong anion exchanger, suspension in 20% ethanol and 150 mM NaCl (40-90 µm)

Stérilité

sterile (Caustic Stable)

Gamme de produits

Fractogel®

Forme

resin

Paramètres

240 cm/hr flow rate
8 bar max. pressure

Groupe de la matrice active

methacrylate

Taille moyenne des particules

40-90 μm

Capacité

100 mg binding capacity (BSA/mg of resin)

Température de transition

flash point 35 °C (calculated)

Densité

1.430 g/cm3 at 20 °C

Masse volumique apparente

1000 kg/m3

Application(s)

gene therapy
mAb
recombinant protein

Technique de séparation

anion exchange
strong anion exchange

Température de stockage

no temp limit

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Strong anion exchange Fractogel® resin featuring the tentacle technology with a trimethylammoniumethyl functional group, for purification of acidic and neutral proteins and peptides from multiple sources, DNA and virus removal, plasmid isolation, vaccine purification, and more

Caractéristiques et avantages

Fractogel® EMD TMAE (M) enables:

  • High protein loading conditions resulting in good selectivity and resolution with the tentacle technology
  • Excellent binding to large viruses at increased loading
  • Homogenous binding with high selectivity and purity
  • Reduce operating costs and resin replacement with enduring durability - allowing for multiple cycles of column regeneration and sanitization
  • Compatibility with 2.5 % (v/v) aqueous benzyl alcohol containing 150 mM NaCl storage solution

Conditionnement

  • 1.16881.0100: Fractogel® EMD TMAE (M) Resin 100ml
  • 1.16881.0010: Fractogel® EMD TMAE (M) Resin 10ml
  • 1.16881.0500: Fractogel® EMD TMAE (M) Resin 500ml
  • 1.16881.0050: Fractogel® EMD TMAE (M) Resin 50ml
Plastic bottle

Remarque sur l'analyse

Appearance: Milky turbid suspension, free from impurities (foreign particles)
Microscopic evaluation: Uniform spherical particles,no agglomerates,no fines
Extractable matter (water): ≤ 0.03 %
Cerium: ≤ 1 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 1.0 bar
Particle size (d10): 37 - 45 µm
Particle size (d50): 48 - 60 µm
Particle size (d90): 63 - 77 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Protein binding capacity (bovine serum albumin): 80 - 120 mg/ml
Functional test (b:a): ≤ 0.25
Functional test: Separation of conalbumin and human serum albumin

Informations légales

FRACTOGEL is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Outil de sélection de produits.

Pictogrammes

Flame
GHS02

Mention d'avertissement

Warning

Mentions de danger

H226

Classification des risques

Flam. Liq. 3

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

95.0 °F

Point d'éclair (°C)

35 °C

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Articles

Cost Modeling Vaccine Manufacturing: Estimate Production Costs for mRNA and other Vaccine Modalities

A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.

Egg-based and Cell-based Influenza Vaccine Manufacturing Methods

Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.

Developing and Manufacturing Attenuated Viral Vaccines

Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.

Virus-like Particle (VLP) Vaccine Bioprocessing and Formulation Steps

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

Afficher tout

Contenu apparenté

Adenovirus Vaccine Manufacturing Process

This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique